p90 ribosomal S6 kinase: a potential therapeutic target in lung cancer.
p90 ribosomal S6 kinase: a potential therapeutic target in lung cancer.
复制标题
DOI：
10.1186/s12967-016-0768-1
复制
发表时间：
2016-01-14
影响因子：
7.4
通讯作者：
Mraiche F
中科院分区：
文献类型：
--
作者：
Poomakkoth N;Issa A;Abdulrahman N;Abdelaziz SG;Mraiche F
一项全球癌症调查显示，肺癌是全球男性新发癌症病例和癌症死亡的最常见原因。肺癌的死亡率比乳腺癌、前列腺癌和结肠直肠癌的死亡率总和还要高。肺癌的两种主要组织学类型是非小细胞肺癌（NSCLC），约占85%的病例，小细胞肺癌占15%的病例。非小细胞肺癌是一种更为普遍的肺癌，通常在晚期才被诊断出来，预后很差。许多因素已被证明有助于人类肺癌的发展，包括吸烟、接触环境致癌物（石棉或氡）和遗传因素。尽管在治疗方面取得了进展，但肺癌仍然是全球癌症死亡的主要原因之一。有趣的是，在过去的25年中，肺癌患者的总体5年生存率并没有明显的变化。因此，迫切需要新的、更有效的非小细胞肺癌治疗方法和策略。p90核糖体S6激酶（RSK）是一种丝氨酸苏氨酸激酶，位于Ras-MAPK（丝裂原活化蛋白激酶）级联的下游，已被证明通过间接（例如，转录因子的调节）或直接影响细胞周期机制参与各种恶性肿瘤细胞增殖的调节。在包括肺癌在内的多种癌症中，RSK的表达增加已被证实。本文综述了RSK在肺癌中的作用及其潜在的治疗应用。
A global survey of cancer has shown that lung cancer is the most common cause of the new cancer cases and cancer deaths in men worldwide. The mortality from lung cancer is more than the combined mortality from breast, prostate and colorectal cancers. The two major histological types of lung cancer are non-small cell lung cancer (NSCLC) accounting for about 85 % of cases and small cell lung cancer accounting for 15 % of cases. NSCLC, the more prevalent form of lung cancer, is often diagnosed at an advanced stage and has a very poor prognosis. Many factors have been shown to contribute to the development of lung cancer in humans including tobacco smoking, exposure to environmental carcinogens (asbestos, or radon) and genetic factors. Despite the advances in treatment, lung cancer remains one of the leading causes of cancer death worldwide. Interestingly, the overall 5 year survival from lung cancer has not changed appreciably in the past 25 years. For this reason, novel and more effective treatments and strategies for NSCLC are critically needed. p90 ribosomal S6 kinase (RSK), a serine threonine kinase that lies downstream of the Ras–MAPK (mitogen activated protein kinase) cascade, has been demonstrated to be involved in the regulation of cell proliferation in various malignancies through indirect (e.g., modulation of transcription factors) or direct effects on the cell-cycle machinery. Increased expression of RSK has been demonstrated in various cancers, including lung cancer. This review focuses on the role of RSK in lung cancer and its potential therapeutic application.